Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

VOLUNTARY ANNOUNCEMENT ENTERING INTO THE COOPERATION FRAMEWORK AGREEMENT WITH ZHEJIANG ANZHEN'ER MEDICAL ARTIFICIAL INTELLIGENCE TECHNOLOGY CO., LTD.

This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has entered into a cooperation framework agreement with Zhejiang Anzhen'er Medical Artificial Intelligence Technology Co., Ltd. (浙江省安診兒醫學人工智能科技有限公司) ("**Anzhen'er**") to carry out cooperation centering on medical imaging artificial intelligence, primary-level imaging cloud services and medical data products, with a cooperation term of three years from the date of signing.

Both parties intend to combine the multimodal medical imaging capabilities of the Group's iMedImage® with Anzhen'er's unique resources, with focus on pre-diagnosis consultations, initial imaging screening and report interpretation, to jointly build a provincial-level capability base for "digital and intelligent imaging" and establish a provincial benchmark for the application of medical large models; leverage the pilot test base operations and medical institution synergy resources of Anzhen'er to explore an imaging cloud service model of "examination at the primary level, identification in the cloud, and review at the provincial level", jointly building the Zhejiang provincial medical imaging AI-assisted diagnosis cloud platform; and jointly develop high-quality medical datasets, artificial intelligence training corpora, as well as scientific research and data analysis products, while exploring new models for the capitalization of medical data.

The Board believes that this cooperation will help combine the Group's medical imaging foundation model and software and hardware product capabilities with the medical resource coordination, clinical scenario organization, and achievement transformation support of the national pilot base, drive collaborative innovation among medical institutions, scientific research institutions, and enterprises around clinical needs through specific projects, explore the research and development, validation, and application of high-quality datasets, disease-specific models, and innovative products, and expand the upper limit of medical scientific research and diagnostic and treatment innovation. The Group also intends to further expand its model services, explore a pay-per-use model based on Token (a unit of measurement for information processed by models) consumption, support medical institutions in invoking high-quality imaging analysis capabilities on demand, lower application thresholds, promote the extension of services to primary care and out-of-hospital health management, expand the commercialisation space for model services, raise the baseline of primary diagnosis and treatment capabilities, and, by creating a new Zhejiang model for "Healthy China", enable artificial intelligence technology to more quickly benefit more people. The collaboration will expand the commercialization potential of model services and advance the application of artificial intelligence in disease prevention, health risk prediction and diagnosis and treatment, which aligns with the interests of the Company and its shareholders as a whole.

About the Group

The Group is a technology company dedicated to revolutionizing medical diagnosis through artificial intelligence. The Group has developed iMedImage®, a foundation model that serves as the "core general-purpose brain" for medical imaging, and has built upon it the iMedLoop™ medical imaging AI research and production acceleration platform. This platform functions like a smart factory, combining medical imaging data with doctors' clinical experience. It not only assists experts in developing new models and research tools more efficiently and expanding the upper limits of medical research and diagnostic innovation; but also transforms expert experience into replicable and deployable models and products, so as to improve the efficiency and quality of medical imaging diagnostics.

About Anzhen'er

Anzhen'er was jointly established and funded by Hangzhou Iron & Steel Group and Ant Group, and is positioned as a provincial-level healthcare artificial intelligence infrastructure platform under the guidance of the Health Commission of Zhejiang Province. Anzhen'er is an independent third party of the Company. As the operating entity of the National Artificial Intelligence Application Pilot Base (Medical) in Zhejiang, Anzhen'er possesses comprehensive capabilities including national-level platform operation, large-scale application of AI agents, medical data governance and hybrid cloud computing power. Leveraging the five major centers of the base, including computing power assurance, data support, model research and development, verification and evaluation, and achievement transformation, it provides full-chain support ranging from proof of concept and R&D testing to industrialized application.

Forward-looking Statement

As of the date of this announcement, both parties have not entered into any specific agreement with respect to specific cooperation projects, and any specific services and fee arrangements are subject to further negotiation and determination. The implementation of any specific cooperation project and its expected benefits remain subject to further negotiation between both parties, relevant technical and commercial feasibility, and the requirements of applicable laws and regulations, and therefore are subject to uncertainties. The cooperation as set out herein does not currently constitute any revenue or profit forecast or commitment of the Group. The Company will make further announcement(s) in due course in accordance with the requirements of the Listing Rules and applicable laws and regulations.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board, Executive Director and General Manager

Hangzhou, PRC, September 11, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.